KemPharm Appoints Tamara A. Seymour to Board of Directors
August 18 2021 - 4:45PM
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical
company focused on the discovery and development of proprietary
prodrugs, announced today the appointment of Tamara A. Seymour to
serve on its Board of Directors and as Chair of the Audit
Committee.
Ms. Seymour brings to KemPharm more than 30
years of life sciences industry experience, including 20 years in
the role of chief financial officer. She currently serves as a
board member and audit committee chair of Artelo Biosciences, Inc.
and Kintara Therapeutics, Inc., both publicly-traded clinical-stage
biopharmaceutical companies.
“The addition of Tamara to our Board of
Directors and her appointment as Chair of the Audit Committee comes
at an important phase in the evolution of KemPharm and continues
what has been a transformative period for the company,” said Travis
C. Mickle, Ph.D., KemPharm’s Chairman, President and Chief
Executive Officer. “Tamara possesses an unrivaled combination of
financial and life sciences industry experience, which will bring
new perspective and a depth of business acumen that will benefit
our shareholders as we seek to leverage our strong financial
position to target organic and external growth opportunities that,
we believe, will ultimately build shareholder value. On behalf of
the Board, I am pleased to welcome Tamara to KemPharm and look
forward to benefitting from her knowledge and expertise.”
Ms. Seymour has served as CFO for several
companies, including Signal Genetics, Inc. (now Viridian
Therapeutics, Inc.), a publicly-traded molecular diagnostics
company, HemaQuest Pharmaceuticals, Inc., a venture-backed
clinical-stage drug development company and Favrille, Inc. (now MMR
Global, Inc.), a publicly-traded clinical-stage drug development
company, and Interim CFO for Immunic, Inc., a publicly-traded
clinical-stage drug development company. Her extensive experience
includes leading multiple private and public financings, M&A
transactions, the initial public offering for Favrille, as well as
leading finance, investor relations, human resources,
administration, and managed care payor reimbursement functions.
Ms. Seymour also served in public accounting for
eight years, primarily with Deloitte & Touche LLP and
PricewaterhouseCoopers LLP. Ms. Seymour is a Certified Public
Accountant (inactive). She earned an MBA, emphasis in Finance, from
Georgia State University, and a BBA, emphasis in Accounting, from
Valdosta State University.
"It is an honor to join the KemPharm Board at
this exciting and transformational juncture for the Company. I look
forward to working with the Board and management to build upon the
work that has been done to create long-term value for all
stakeholders," said Ms. Seymour.
About KemPharm:
KemPharm is a specialty pharmaceutical company
focused on the discovery and development of proprietary prodrugs to
treat serious medical conditions through its proprietary LAT®
(Ligand Activated Therapy) technology. KemPharm utilizes its
proprietary LAT® technology to generate improved prodrug versions
of FDA-approved drugs as well as to generate prodrug versions of
existing compounds that may have applications for new disease
indications. KemPharm’s prodrug product candidate pipeline is
focused on the high need areas of attention deficit hyperactivity
disorder, or ADHD, stimulant use disorder (SUD) and CNS rare
diseases, including idiopathic hypersomnia (IH). KemPharm’s lead
clinical development candidate for the treatment of SUD, KP879, is
based on its prodrug of d-methylphenidate, known as
serdexmethylphenidate (SDX). In addition, KemPharm has received FDA
approval for AZSTARYSTM, a new once-daily treatment for ADHD in
patents age six years and older, and for APADAZ®, an
immediate-release combination product containing benzhydrocodone, a
prodrug of hydrocodone, and acetaminophen. For more information on
KemPharm and its pipeline of prodrug product candidates visit
www.kempharm.com or connect with us on Twitter, LinkedIn, Facebook
and YouTube.
Caution Concerning Forward Looking
Statements:
This press release may contain forward-looking
statements made in reliance upon the safe harbor provisions of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements include all statements that do not
relate solely to historical or current facts and can be identified
by the use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements are
based on information currently available to KemPharm and its
current plans or expectations and are subject to a number of
uncertainties and risks that could significantly affect current
plans. Risks concerning KemPharm’s business are described in detail
in KemPharm’s Quarterly Report on Form 10-Q for the quarter ended
June 30, 2021, and KemPharm’s other filings with the Securities and
Exchange Commission. KemPharm is under no obligation to, and
expressly disclaims any such obligation to, update or alter its
forward-looking statements, whether as a result of new information,
future events or otherwise.
KemPharm Contacts:
Tiberend Strategic Advisors, Inc.Jason
Rando/Maureen McEnroe, CFA(212) 375-2665 /
2664jrando@tiberend.commmcenroe@tiberend.com
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Sep 2023 to Sep 2024